Altshuler Shaham LTD Neurocrine Biosciences Inc Transaction History

Altshuler Shaham LTD

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$106.07 - $132.76 $5,833 - $7,301	-55 Reduced 26.44%	153 $20,000
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $19,556 - $24,356	208 New	208 $23,000
Q1 2023 May 09, 2023	SELL	$94.11 - $123.02 $47,055 - $61,510	-500 Closed	0 $0
Q4 2022 May 09, 2023	SELL	$106.72 - $127.06 $7,577 - $9,021	-71 Reduced 12.43%	500 $59,000
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $13,160 - $15,416	-143 Reduced 20.03%	571 $59,000
Q2 2022 Aug 10, 2022	BUY	$75.79 - $100.07 $21,145 - $27,919	279 Added 64.14%	714 $70,000
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $31,515 - $41,242	435 New	435 $41,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $56,143 - $69,981	-646 Closed	0 $0
Q3 2020 Nov 10, 2020	BUY	$96.16 - $135.15 $17,212 - $24,191	179 Added 38.33%	646 $62,000
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $39,737 - $60,878	467 New	467 $57,000
Q1 2020 May 12, 2020	SELL	$75.11 - $113.76 $19,678 - $29,805	-262 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$86.8 - $118.57 $14,408 - $19,682	166 Added 172.92%	262 $28,000
Q3 2019 Nov 12, 2019	BUY	$83.82 - $101.5 $8,046 - $9,744	96 New	96 $9,000

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Altshuler Shaham LTD, based on Form 13F filings with the SEC.

Stay updated on Altshuler Shaham LTD with notifications on news.